Abstract
Haloperidol (30 nM, 3 microM) was found to increase prolactin release from GH4C 1 cells transfected with the D2 receptor cDNA (GH4ZR 7) and from wild-type (untransfected) GH 3 cells, but not from wild-type GH4C 1 cells. In addition, haloperidol (3 microM) stimulated cAMP formation in GH 3 cells. It is suggested that haloperidol may act as an inverse agonist rather than as a neutral antagonist at dopaminergic D2 receptors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-3-isobutylxanthine / pharmacology
-
Animals
-
Cell Line
-
Cyclic AMP / biosynthesis*
-
Dopamine Agents / pharmacology*
-
Haloperidol / pharmacology*
-
Prolactin / metabolism*
-
Radioimmunoassay
-
Rats
-
Receptors, Dopamine D2 / drug effects*
-
Receptors, Dopamine D2 / genetics
-
Receptors, Dopamine D2 / metabolism
-
Vasoactive Intestinal Peptide / pharmacology
Substances
-
Dopamine Agents
-
Receptors, Dopamine D2
-
Vasoactive Intestinal Peptide
-
Prolactin
-
Cyclic AMP
-
Haloperidol
-
1-Methyl-3-isobutylxanthine